胸腺切除治疗合并胸腺瘤的重症肌无力患者:一石二鸟
该回顾性研究纳入1994年至2016年接受扩大胸腺切除术的219例合并胸腺瘤的重症肌无力患者,分析肿瘤学与神经学结局。结果显示早期与晚期患者的总生存和无病生存有统计学差异,术后34.2%达到完全稳定缓解,肿瘤复发率较低。结论认为手术是胸腺瘤合并重症肌无力的基石治疗。
要点
- 扩大胸腺切除术对合并胸腺瘤的重症肌无力患者可同时改善肿瘤学与神经学结局。
- 早期与晚期胸腺瘤患者的总生存和无病生存存在统计学差异。
- 术后34.2%患者达到完全稳定缓解,15.1%出现复发。
核心结论
- 手术是胸腺瘤合并重症肌无力治疗的基石,扩大胸腺切除术可带来良好的肿瘤学结局和显著的神经学改善。
主要发现
- B2型胸腺瘤最常见(24.2%),Masaoka分期IIB期最常见(37.9%)。
- 早期与晚期患者的总生存和无病生存有统计学差异。
- 随访期间33例(15.1%)复发,其中21例接受再次手术。
- 神经学结局:75例(34.2%)达到完全稳定缓解,84例(38.4%)达到药物缓解,51例(23.3%)症状改善,9例(4.1%)无变化或加重。
关键数值与推荐
- 完全稳定缓解75例(34.2%),药物缓解84例(38.4%),症状改善51例(23.3%),无变化或加重9例(4.1%)。
- 复发33例(15.1%),其中21例接受再次手术。
- B2型胸腺瘤占24.2%,Masaoka IIB期占37.9%。
临床怎么用
- 对合并胸腺瘤的重症肌无力患者,可考虑按Masaoka建议行扩大胸腺切除术以兼顾肿瘤控制与神经症状改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thymoma and myasthenia gravis share several pathogenetic aspects including the role of surgery as a therapeutic option. Extended thymectomy is associated with excellent survival and good local control, especially in early stages, and its role for the neurologic disease has been recently validated. The aim of this study is evaluating oncologic and neurologic outcomes of myasthenic patients with thymoma who underwent extended thymectomy. METHODS: We retrospectively collected surgical, oncologic, and neurologic data of all myasthenic patients with thymoma who underwent extended thymectomy at our department from January 1994 to December 2016. Clinical and pathologic data, neurologic remission rate, and overall survival and disease-free interval were analyzed. RESULTS: In all, 219 patients underwent extended thymectomy. The B2 histotype was the most represented thymoma (24.2%), and the most prevalent pathologic Masaoka stage was IIB (37.9%). The overall survival and disease-free survival were statistically different between early stage and advanced stage. During the surveillance, 33 patients (15.1%) had recurrences, treated in 21 cases with iterative surgery. Regarding neurologic outcomes, 75 patients (34.2%) reached a complete stable remission, 84 (38.4%) a pharmacologic remission, 51 (23.3%) had an improvement of their symptoms, and in 9 patients (4.1%) myasthenia was unchanged or worsened. CONCLUSIONS: Surgery is a cornerstone in the treatment of patients with both thymoma and myasthenia gravis. Extended thymectomy, as proposed by Masaoka, offers considerable oncologic outcomes with an excellent survival and low recurrence rate of thymoma; moreover, surgery leads to remarkable neurologic results.
引用
- Aprile V, Korasidis S, Bacchin D, et al. Thymectomy in Myasthenic Patients With Thymoma: Killing Two Birds With One Stone. Ann Thorac Surg. 2021. PMID: 33358889. doi:10.1016/j.athoracsur.2020.12.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。